D
David W. Fry
Researcher at Pfizer
Publications - 31
Citations - 3258
David W. Fry is an academic researcher from Pfizer. The author has contributed to research in topics: Receptor tyrosine kinase & Tyrosine kinase. The author has an hindex of 18, co-authored 31 publications receiving 3001 citations. Previous affiliations of David W. Fry include Autonomous University of Barcelona.
Papers
More filters
Journal Article
Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts
David W. Fry,Patricia J. Harvey,Paul R. Keller,William Elliott,Maryanne Meade,Erin Trachet,Mudher Albassam,Xianxian Zheng,Wilbur R. Leopold,Nancy Pryer,Peter L. Toogood +10 more
TL;DR: Results indicate that inhibition of Cdk4/6 alone is sufficient to cause tumor regression and a net reduction in tumor burden in some tumors.
Journal ArticleDOI
Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6.
Peter L. Toogood,Patricia J. Harvey,Joseph T. Repine,Derek James Sheehan,Scott Norman Vanderwel,Hairong Zhou,Paul R. Keller,Mcnamara Dennis Joseph,Debra Ann Sherry,Tong Zhu,Joanne Brodfuehrer,Chung Choi,Mark R. Barvian,David W. Fry +13 more
TL;DR: It is demonstrated that the modification of pyrido[2,3-d]pyrimidin-7-ones to include a 2-aminopyridine side chain at the C2-position provides inhibitors with exquisite selectivity for Cdk4/6 in vitro.
Journal ArticleDOI
Drug‐induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: implications for cancer therapy
Ami Citri,Iris Alroy,Sara Lavi,Chanan Rubin,Wanping Xu,Nicolas Grammatikakis,Cam Patterson,Len Neckers,David W. Fry,Yosef Yarden +9 more
TL;DR: An unexpected activity of TKIs is reported: along with inhibition of tyrosine phosphorylation, they enhance ubiquitylation and accelerate endocytosis and subsequent intracellular destruction of ErbB‐2 molecules.
Journal Article
PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner.
Monique Bos,John Mendelsohn,Young Mee Kim,Joan Albanell,David W. Fry,David W. Fry,José Baselga,José Baselga +7 more
TL;DR: C Cotreatment with C225, an anti-EGF receptor-blocking monoclonal antibody, further enhanced the antitumor activity of PD153035, suggesting mechanisms of action for C225 other than competition with ligand binding.
Journal ArticleDOI
CI-1033, a pan-erbB tyrosine kinase inhibitor.
TL;DR: In vitro studies of human cancer cell lines indicate that CI-1033 results in prompt, potent, and sustained inhibition of tyrosine kinase activity, which holds significant potential for use in a broad range of solid tumors.